What is Kintara Therapeutics Receivables Turnover?
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kintara Therapeutics's Revenue for the
three
months ended in Dec. 2023 was $0.00 Mil. Kintara Therapeutics's average Accounts Receivable for the
three
months ended in Dec. 2023 was $0.10 Mil.
Kintara Therapeutics Receivables Turnover Historical Data
The historical data trend for Kintara Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kintara Therapeutics's Receivables Turnover
For the Biotechnology subindustry, Kintara Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintara Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Kintara Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Kintara Therapeutics Receivables Turnover Related Terms
Thank you for viewing the detailed overview of Kintara Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintara Therapeutics (Kintara Therapeutics) Business Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KTRA has been successfully added to your 